MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

Home・Akciju saraksts・Natera Inc

Natera Inc

Slēgts

SektorsVeselības aprūpe

208.3 1.75

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

202.42

Max

209.48

Galvenie mērījumi
By Trading Economics
Ienākumi	135M 47M
Pārdošana	73M 666M
EPS	0.36
Peļņas marža	7.101
Darbinieki	6,135
EBITDA	41M -35M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+27.82% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 7. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-157M 29B
Iepriekšējā atvēršanas cena	206.55
Iepriekšējā slēgšanas cena	208.3

Ziņu noskaņojums

By Acuity

17%

83%

38 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

153.79 / N/A Atbalsts un pretestība

Natera Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 7. apr. 17:26 UTC

Galvenie ziņu notikumi

EIA Raises Oil-Price Forecasts as War in Middle East Continues

2026. g. 7. apr. 23:55 UTC

Tirgus saruna

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

2026. g. 7. apr. 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Market Talk Roundup: Latest on U.S. Politics

2026. g. 7. apr. 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

2026. g. 7. apr. 23:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

2026. g. 7. apr. 23:42 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 7. apr. 23:42 UTC

Tirgus saruna

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

2026. g. 7. apr. 23:37 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

2026. g. 7. apr. 23:15 UTC

Tirgus saruna

Galvenie ziņu notikumi

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

2026. g. 7. apr. 23:04 UTC

Galvenie ziņu notikumi

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

2026. g. 7. apr. 23:04 UTC

Galvenie ziņu notikumi

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

2026. g. 7. apr. 23:03 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 7. apr. 23:03 UTC

Tirgus saruna

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

2026. g. 7. apr. 23:01 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

2026. g. 7. apr. 22:58 UTC

Galvenie ziņu notikumi

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

2026. g. 7. apr. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

2026. g. 7. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 7. apr. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 7. apr. 19:45 UTC

Tirgus saruna

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

2026. g. 7. apr. 19:17 UTC

Galvenie ziņu notikumi

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

2026. g. 7. apr. 19:16 UTC

Tirgus saruna

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

2026. g. 7. apr. 19:07 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 7. apr. 19:07 UTC

Tirgus saruna

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

2026. g. 7. apr. 18:41 UTC

Iegādes, apvienošanās, pārņemšana

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

2026. g. 7. apr. 18:40 UTC

Iegādes, apvienošanās, pārņemšana

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

2026. g. 7. apr. 18:39 UTC

Iegādes, apvienošanās, pārņemšana

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

2026. g. 7. apr. 18:24 UTC

Galvenie ziņu notikumi

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

2026. g. 7. apr. 17:08 UTC

Tirgus saruna

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

2026. g. 7. apr. 16:21 UTC

Galvenie ziņu notikumi

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

2026. g. 7. apr. 16:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Natera Inc Prognoze

Cenas mērķis

By TipRanks

27.82% augšup

Prognoze 12 mēnešiem

Vidējais 261.86 USD 27.82%

Augstākais 300 USD

Zemākais 215 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Natera Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

14 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 14 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Natera Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

153.79 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bullish event.

Noskaņojums

By Acuity

38 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.